Regulation of Fat-stimulated Neurotensin Secretion in Healthy Subjects
|ClinicalTrials.gov Identifier: NCT00541762|
Recruitment Status : Completed
First Posted : October 10, 2007
Last Update Posted : March 10, 2015
Context: Cholecystokinin (CCK) and neurotensin are stimulated during meal intake by the presence of fat in the small intestine. The sequence of events suggests that fat hydrolysis is crucial for triggering the release.
Objectives: The aim of this study was therefore to investigate whether CCK mediated the effect of intraduodenal (ID) fat on neurotensin secretion via CCK-1 receptors.
|Condition or disease||Intervention/treatment||Phase|
|Healthy||Dietary Supplement: Fat perfusion to the small intestine||Not Applicable|
Setting: Single center study; 34 male volunteers were studied in consecutive, randomized, double blind, crossover studies.
Subjects and Methods: CCK and neurotensin release were quantified in: 1) 12 subjects receiving an ID fat infusion with or without 60 mg orlistat, an irreversible inhibitor of gastrointestinal lipases, in comparison to vehicle. 2) 12 subjects receiving ID long chain fatty acids (LCF), ID medium chain fatty acids (MCF) or ID vehicle. 3) 10 subjects receiving ID LCF with and without the CCK-1 receptor antagonist dexloxiglumide (DEXLOX) or ID vehicle plus IV saline (placebo). Hormone concentrations were measured by specific RIA systems.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||34 participants|
|Intervention Model:||Crossover Assignment|
|Primary Purpose:||Basic Science|
|Official Title:||Mechanistic Study (Physiology)|
|Study Start Date :||January 2006|
|Actual Primary Completion Date :||March 2007|
|Actual Study Completion Date :||March 2007|
A, 3; B, 3; C, 3
A, 3: Fat with and without orlistat or placebo. B, 3: LCF vs MCF vs placebo. C, 3: LCF with and without DEXLOX or placebo.
Dietary Supplement: Fat perfusion to the small intestine
- Neurotensin plasma concentrations [ Time Frame: Change in plasma cocnentrations over 2-3 hours ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00541762
|Clinical Research Center, University Hospital|
|Basel, Switzerland, CH-4031|
|Principal Investigator:||Juergen Drewe, MD||University Hospital, 4031 Basel, Switzerland|
|Principal Investigator:||Christoph Beglinger, MD||Department of Research and Clinical Pharmacology, University Hospital, Basel Switzerland|